Project Grant HT94252510555
Award Date
9/1/25
Completion Date
8/31/27
Dollars Obligated
$352K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
The federal Project Grant award of $924,001.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research by the Sloan-Kettering Institute for Cancer Research to investigate the cellular and molecular origins of non-small cell lung cancer (NSCLC) brain metastasis. The research aims to enhance understanding of the mechanisms driving NSCLC brain metastasis, with the goal of developing innovative therapeutic...
Sloan-Kettering Institute For Cancer Research was awarded a $796,500 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of July 15, 2023 through July 14, 2026. The grant will support research to develop novel tools to improve responses to DNA-damaging therapeutics in metastatic breast cancer. As the prime recipient, Sloan-Kettering Institute For Cancer Research will leverage its expertise in cancer biology,...
The Sloan-Kettering Institute for Cancer Research was awarded a $707,346 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2024, supports Sloan-Kettering's cancer research initiatives, including investigations into the tumor microenvironment, mechanisms of metastasis, epigenetic alterations in cancer, resistance to cancer therapies, aging-related biology, and hematologic malignancies....
The Defense Health Agency awarded a $619,500 Project Grant to the Sloan-Kettering Institute for Cancer Research, a non-profit organization in New York, NY. The grant is funded through the Military Medical Research and Development (CFDA 12.420) program and will support research to investigate the immunogenicity and targeting of shared neoantigens in adenoid cystic cancer over a 3-year period from September 1, 2023 to August 31, 2026. The research aims to transform health care for Service...
The federal Project Grant award of $923,805.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant will fund the "Systematic Functional Dissection of Cancer Cell States in Lung Tumors" research project at the Sloan-Kettering Institute for Cancer Research in New York, NY. The project aims to advance understanding of cancer cell biology and develop novel therapeutic approaches for lung cancer, with...
Sloan-Kettering Institute For Cancer Research was awarded a $845,789 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of July 1, 2023 to June 30, 2026. The grant will support research to discover biomarkers and address outcome disparities for prostate cancer through exploiting real-world clinical genomic data. As the prime recipient, Sloan-Kettering Institute For Cancer Research will leverage its expertise...
This $176,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research by the Sloan-Kettering Institute for Cancer Research to investigate the interactions of mitochondrially encoded complex I mutations with hypoxia and antitumor immune response in chromophobe renal cell carcinoma. The research aims to further the understanding of cancer biology and potential therapeutic approaches, with a focus on conditions...
The federal Project Grant award, totaling $384,342.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute For Cancer Research, a non-profit organization in New York, NY. The award, effective June 15, 2024 through June 14, 2027, supports the development of generalizable and reliable AI for early detection of melanoma. Through this funding, the Sloan-Kettering Institute For Cancer Research will...
This $176,000 Project Grant awarded by the Department of Defense (DOD) through the Military Medical Research and Development program (CFDA 12.420) supports research by the Sloan-Kettering Institute for Cancer Research to define the biology of and identify therapeutic vulnerabilities in DCK12-inactivated prostate cancer. The award period is from April 1, 2024 to March 31, 2025. As a non-profit organization focused on cancer research and patient care, Sloan-Kettering Institute has previously...
The federal Project Grant award, issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), provides $1,944,610.00 to the Sloan-Kettering Institute for Cancer Research to conduct research on understanding tumorigenesis and identifying therapeutic targets in CDK12-mutant prostate cancer. The 3-year project, running from April 1, 2025 to March 31, 2028, aims to advance the scientific understanding and treatment of this specific form of prostate...